|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1996-12-17
|
|
pubmed:abstractText |
The combination of carboplatin, methotrexate and vinblastine (M-CAVI) is an active and well-tolerated regimen for patients with bladder cancer who are ineligible for cisplatin-based regimens. We have prospectively randomized patients with locally advanced (T2-4 N0 M0) or locoregional (Tx N1 M0) bladder cancer suitable for subsequent surgical treatment to M-VAC or M-CAVI chemotherapy.
|
|
pubmed:language |
spa
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0004-0614
|
|
pubmed:author |
pubmed-author:AlbanellJJ,
pubmed-author:Banús GassolJ MJM,
pubmed-author:Bellmunt MolinsJJ,
pubmed-author:Casado CoboSS,
pubmed-author:ErelAA,
pubmed-author:López PalaciosM AMA,
pubmed-author:Lorente GarínJ AJA,
pubmed-author:Morote RoblesJJ,
pubmed-author:RibasAA,
pubmed-author:Solé CalvoL ALA,
pubmed-author:de Torres MateosJ AJA
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
49
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
465-72
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:8766083-Adolescent,
pubmed-meshheading:8766083-Adult,
pubmed-meshheading:8766083-Aged,
pubmed-meshheading:8766083-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8766083-Carboplatin,
pubmed-meshheading:8766083-Cisplatin,
pubmed-meshheading:8766083-Doxorubicin,
pubmed-meshheading:8766083-Female,
pubmed-meshheading:8766083-Humans,
pubmed-meshheading:8766083-Male,
pubmed-meshheading:8766083-Methotrexate,
pubmed-meshheading:8766083-Middle Aged,
pubmed-meshheading:8766083-Neoplasm Staging,
pubmed-meshheading:8766083-Survival Rate,
pubmed-meshheading:8766083-Urinary Bladder Neoplasms,
pubmed-meshheading:8766083-Vinblastine
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
[Preliminary results of a phase II randomized controlled trial comparing M-VAC and M-CAVI in patients with bladder cancer (T2-4 N0-1 M0)].
|
|
pubmed:affiliation |
Sección de Oncología Médica y Servicio de Urología, Hospital General Universitario Vall d'Hebron, Barcelona, España.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
English Abstract,
Randomized Controlled Trial
|
